Overcoming Black Americans’ Psychological and Cognitive Barriers to Clinical Trial Participation: Effects of News Framing and Exemplars

Hu, Sisi; Lee, Namyeon; Hong, Yoorim; Lee, Sungkyoung; Hinnant, Amanda

doi:10.1080/10410236.2022.2105619

Cited by 5 publications

(1 citation statement)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study pointed out that participative cognition has an influential impact on the psychological well-being of cancer patients during drug clinical trials ( Guangju et al, 2022 ). Participative cognition is associated with information gathering ( Kirkpatrick et al, 2023 ), interpersonal trust with members of the clinical trial team ( Hurd et al, 2017 ), and self-efficaciousness ( Gouveia et al, 2022 ). For example, item 3, “I am prepared to deal with any challenges that may arise during the drug clinical trial,” reflects the participation feelings that cancer patients perceive from affirming their own abilities and interpersonal trust with the clinical trial team.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of a drug clinical trial participation feelings questionnaire for cancer patients

Guo,

Xing,

Zhao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

ObjectiveThe study was designed to develop and validate a new drug clinical trial participation feelings questionnaire (DCTPFQ) for cancer patients.MethodsData collection and analysis involved a combination of qualitative and quantitative methods. There were two phases to this study. Phase Ⅰ involved developing a questionnaire to establish a list of items to be included in the pool: A theoretical framework was constructed based on the transitions theory and the Roper–Logan–Tierney theory. After incorporating a theoretical framework, interviewing participants, and reviewing the literature, 44 items were generated. After a Delphi consultation and a pilot test, 36 items proceeded to item analysis and exploratory factor analysis (EFA), and a four-factor structure with 21 items was formed. Confirmatory factor analysis (CFA), test–retest reliability, criteria-related validity, and internal consistency tests were conducted in phase II to examine the psychometric properties.ResultsThere were 21 items on the DCTPFQ, ranging from 1 (fully disagree) through 5 (fully agree). As a result of EFA and CFA, the four factors of DCTPFQ could be verified, including cognitive engagement, subjective experience, medical resources, and relatives and friends’ support. Test–retest reliability of the DCTPFQ was 0.840, and Cronbach’s alpha was 0.934. DCTPFQ is significantly correlated with the Fear of Progression Questionnaire—short form (r = 0.731, p < 0.05) and the Mishel’s Uncertainty in Illness Scale (r = 0.714, p < 0.05).ConclusionThe DCTPFQ is a useful tool for measuring the drug clinical trial participation feelings among cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%